American Century Companies’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$856K Hold
109,011
– – ﹤0.01% 2445
2026
Q1
$380K Sell
109,011
-4,749
-4% -$17.1K ﹤0.01% 2585
2025
Q4
$389K Hold
113,760
– – ﹤0.01% 2572
2025
Q3
$572K Hold
113,760
– – ﹤0.01% 2476
2025
Q2
$390K Sell
113,760
-2,904
-2% -$7.23K ﹤0.01% 2598
2025
Q1
$260K Sell
116,664
-223
-0.2% -$640 ﹤0.01% 2694
2024
Q4
$342K Sell
116,887
-239
-0.2% -$666 ﹤0.01% 2639
2024
Q3
$305K Sell
117,126
-90
-0.1% -$249 ﹤0.01% 2642
2024
Q2
$347K Sell
117,216
-108
-0.1% -$409 ﹤0.01% 2570
2024
Q1
$531K Sell
117,324
-231
-0.2% -$1.18K ﹤0.01% 2426
2023
Q4
$671K Sell
117,555
-837,068
-88% -$3.88M ﹤0.01% 2244
2023
Q3
$4.39M Sell
954,623
-158,293
-14% -$963K ﹤0.01% 1377
2023
Q2
$7.19M Sell
1,112,916
-179,676
-14% -$1.23M 0.01% 1178
2023
Q1
$9.59M Buy
1,292,592
+4,335
+0.3% +$39.4K 0.01% 1034
2022
Q4
$13.1M Buy
1,288,257
+712,995
+124% +$8.24M 0.01% 875
2022
Q3
$5.69M Buy
+575,262
New +$6.31M 0.01% 1069

Other funds holding ABCL

American Century Companies's ABCL Position: Q2 2026 in Review

American Century Companies held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 109,011 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

American Century Companies first reported a position in ABCL in Q3 2022 and has held it in 16 quarters since. The position peaked at $13.1M in Q4 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • American Century Companies held 109,011 shares of AbCellera Biologics worth $856K as of Q2 2026.
  • American Century Companies left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2445 holding.
  • American Century Companies first reported a position in AbCellera Biologics in Q3 2022 and has held it in 16 quarters since.
  • American Century Companies's AbCellera Biologics position peaked at $13.1M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.